The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in Germany

Abstract Background We analysed the impact of clinical study design for oncological pharmaceuticals on the subsequent price negotiations after early benefit assessment between pharmaceutical companies and the German National Association of Statutory Health Insurance Funds. The analysis was conducted...

Full description

Saved in:
Bibliographic Details
Main Authors: C. M. Dintsios, I. Beinhauer
Format: Artigo
Language:Inglês
Published: BMC 2020-03-01
Series:Health Economics Review
Subjects:
Study design
Negotiated prices
Oncological drugs
Pharmaceutical companies
Payers
German statutory health insurance
Online Access:http://link.springer.com/article/10.1186/s13561-020-00263-2
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items